Overview

Tech Summary

Promoter Holding

Posts

ZYDUSLIFE

601234567893012345678980123456789.1012345678900123456789
+4.05 (+0.64%)
The current prices are delayed.Login/Sign Upto see live prices.
Previous Close: 634.05
1D
5D
1M
3M
1Y
5Y
MAX
Today's low
635.75
Today's high
644
52 week low
350.25
52 week high
668.75
Volume
586023
About
TECHNICAL SUMMARY
DMA(12)
₹404.22
DMA(50)
₹410.4
DMA(100)
₹389.71
DMA(200)
₹444.11
FUNDEMANTAL SUMMARY
Market Cap
₹64588.48 Cr.
Enterprise Value
₹65178.58 Cr.
No. of Shares
101.22
P/E
25.54
RoE
11.6
Debt/Equity
0.07
Valuations
PE CHART
3032343638
PB CHART
2.22.42.62.83.03.23.4
Promoter Holdings
Public : 7.47%
FII : 4.04%
DII : 13.52%
Promoter : 74.98%
Others : 0%
Charts
DEBT/EQUITY
0.100.200.300.400.500.600.70
Mar, 2019Mar, 2020Mar, 2021Mar, 2022Mar, 2023
ROE VS ROCE
101214161820
Mar, 2019Mar, 2020Mar, 2021Mar, 2022Mar, 2023
ROE
ROCE
REVENUE VS PROFITABILITY (1000CR.)
51015
Mar, 2019Mar, 2020Mar, 2021Mar, 2022Mar, 2023
Revenue
Profit
MARGINS(%)
10152025
Mar, 2019Mar, 2020Mar, 2021Mar, 2022Mar, 2023
Net Margin
Gross Margin
Posts by FrontPage Users
tradeculturee-display-image
Reputation: 6,737  •  Dec 4 2:18 PM


Intraday Trade Setup.
Horizontal resistance breakout in a uptrend give opportunity to grab a momentum up move.

Entry above - 649.50.

TGT- 655,675+
Chartbusters - chart - 233792617

1 Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Dec 1 7:18 PM
Zydus Life gains on USFDA nod for heart drug
Zydus Life gains on USFDA nod for heart drug
Zydus Lifesciences may be eligible for 180 days of shared generic exclusivity for Ivabradine tablets which reduce the risk of hospitalisation for worsening heart failure in adult patients
Moneycontrol

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Zydus Lifesciences has received final approval from the US FDA for its heart drug Ivabradine, which reduces the risk of hospitalisation for worsening heart failure in adult patients.
• The company may be eligible for 180 days of shared generic exclusivit......read more

Vote

Comment
Share
Add a comment
DayTraderVenkat-display-image
Reputation: 56  •  Dec 1 2:04 PM

ZYDUSLIFE 650 CE BUY at 17-18
SL 14
Tgt 22/24/26+
Chartbusters - chart - 232650882

Vote

Comment
Share
Add a comment
K
Reputation: 16  •  Nov 26 11:08 PM

1 Vote

Comment
Share
Add a comment
I
Reputation: 2,532  •  Nov 23 10:28 PM

Vote

Comment
Share
Add a comment
F
Reputation: 41,615  •  Nov 23 1:34 PM


TIME FRAME:-- DAY
Only think for Short from Supply Zone
Chartbusters - chart - 226367848

Vote

Comment
Share
Add a comment
Dhananjay-display-image
Reputation: 27,979  •  Nov 16 7:45 PM

2 Votes

1 Comment
Share
Add a comment
D
Reputation: 13,822  •  Nov 16 4:02 PM

In daily time frame chart analysis 📈📉
If stock will sustain above this trendline then probably we will see upside momentum in this stock that's all are probability not surety
Keep in your radar
For learning purpose
Do your own research analysis
Chartbusters - chart - 220761370

2 Votes

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Nov 10 9:18 PM
Torrent and Zydus sign pact to co-market Saroglitazar for chronic liver diseases in India
Torrent and Zydus sign pact to co-market Saroglitazar for chronic liver diseases in India
Torrent will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones
Moneycontrol

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Torrent Pharmaceuticals Limited and Zydus Lifesciences Limited have joined forces through a licensing and supply agreement to co-market Saroglitazar Mg in India for Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD).
• To......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Nov 10 8:33 PM
Buy Zydus Lifesciences; target of Rs 687 Sharekhan
Buy Zydus Lifesciences; target of Rs 687 Sharekhan
Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 687 in its research report dated November 06, 2023.
Moneycontrol

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Sharekhan has recommended a buy rating on Zydus Lifesciences with a target price of Rs. 687.
• In Q2FY24, the company saw a mixed bag of results with an 8% y-o-y increase in revenue but a 15% q-o-q decline due to lower US sales.
• Despite this, the compa......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Nov 10 8:08 PM
Accumulate Zydus Lifesciences; target of Rs 670: Prabhudas Lilladher
Accumulate Zydus Lifesciences; target of Rs 670: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 670 in its research report dated November 08, 2023.
Moneycontrol

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Prabhudas Lilladher has recommended an accumulate rating on Zydus Lifesciences with a target price of Rs 670.
• ZYDUSLIF's Q2 EBITDA was largely in line with estimates, aided by healthy margins despite negligible gRevlimid sales.
• The company's steady d......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Nov 10 7:43 PM
Neutral Zydus LifeSciences; target of Rs 660: Motilal Oswal
Neutral Zydus LifeSciences; target of Rs 660: Motilal Oswal
Motilal Oswal recommended Neutral rating on Zydus LifeSciences with a target price of Rs 660 in its research report date November 07, 2023.
Moneycontrol

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Motilal Oswal has given a Neutral rating on Zydus LifeSciences with a target price of Rs 660.
• Zydus LifeSciences delivered a marginal miss on its 2QFY24 financial performance, but the outlook is expected to improve with new launches and R&D efforts.
• ......read more

Vote

Comment
Share
Add a comment
Great Eagle Capital-display-image
Reputation: 17,609  •  Nov 8 11:05 PM

#ZYDUSLIFE WEEKLY CHART

ADVANCE VIEW

WEEKLY CHART WILL GIVE GOOD C&H BREAKOUT ABOVE 670 IN CLOSE BASIS.

ONLY ABOVE 670 IS BULLISH FOR 1017 SL 600(WEEKLY CLBS).

Debt Free Pharmaceuticals - Indian - Bulk Drugs & Formln.
Chartbusters - chart - 215641841

1 Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Nov 8 2:55 PM

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Zydus Lifesciences reported a 5.66% increase in net sales and a 53.24% increase in net profit for the September 2023 quarter.
• EBITDA also saw a significant increase of 39.6%.
• The company's EPS has increased from Rs. 5.15 to Rs. 7.91 in the same perio......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Nov 8 2:33 PM

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Zydus Life reported a decrease in net sales for September 2023 compared to the same period in 2022, but a significant increase in net profit and EBITDA.
• The company's EPS has also increased.
• Zydus Life's shares have performed well over the last 6 and......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Nov 7 5:48 PM

𝗡𝗲𝘄𝘀 𝗦𝘂𝗺𝗺𝗮𝗿𝘆
• Zydus Lifesciences reported a 53.2% growth in consolidated net profit for the July-September quarter of FY 2023-2024.
• Revenue for the quarter was 5.6% higher than the previous fiscal year.
• The company's bottomline and revenue have both shown signific......read more

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Oct 31 8:08 PM
Zydus Life to acquire LiqMeds Group for Rs 689 crore
Zydus Life to acquire LiqMeds Group for Rs 689 crore
Zydus added that LiqMeds Group has capabilities and specialisation in development, manufacturing and supply of oral liquid products for global markets, which it currently commercializes through partners.
Moneycontrol

Vote

Comment
Share
Add a comment
Himanshu Trading Zone-display-image
Reputation: 26,425  •  Oct 31 2:29 PM

BUY ZYDUSLIFE ABOVE 579.60 SL 568.20 T1 598.40 T2 620.70
Chartbusters - chart - 206343115

2 Votes

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Oct 30 4:38 PM
Zydus, Sun Pharma to co-market oral drug for anaemia linked to kidney diseases
Zydus, Sun Pharma to co-market oral drug for anaemia linked to kidney diseases
Desidustat is first-of-its-kind oral treatment for anemia associated with Chronic Kidney Disease in India.
Moneycontrol

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Oct 23 3:09 PM
Zydus Lifesciences gain on US FDA approval for diabetic drug
Zydus Lifesciences gain on US FDA approval for diabetic drug
Zydus Lifesciences on October 20 announced that the USFDA approved its New Drug Application (NDA) for ZITUVIOTM (Sitagliptin) tablets, 25 mg, 50 mg, and 100 mg, company said in its statement.
Moneycontrol

Vote

Comment
Share
Add a comment
Rahul seth-display-image
Reputation: 4,665  •  Oct 11 4:26 AM

📈 INTRADAY TRADE 📈
STOCK-: ZYDUS LIFESCIENCES
BUY ABOVE ⬆️ @605
TARGET 🎯:-610,615+++
SELL BELOW ⬇️ @595
TARGET 🎯:-590,585+++
STOPLOSS 📈:- As Per Your Risk Limit.
Chartbusters - chart - 188945297

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Oct 6 9:08 PM
Zydus gets USFDA for nod for neuromuscular drug
Zydus gets USFDA for nod for neuromuscular drug
The Sugammadex injection will be manufactured at the group’s manufacturing facility near Vadodara in Gujarat
Moneycontrol

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Oct 6 5:28 PM
Zydus, Aurobindo subsidiaries recall drugs in the US market
Zydus, Aurobindo subsidiaries recall drugs in the US market
The recalls were reported in the daily U.S. Food and Drug Administration Recall Information updates
Moneycontrol

Vote

Comment
Share
Add a comment
Trending Trade-display-image
Reputation: 2,062  •  Oct 5 5:56 AM

1 DAY TF
FLAG PATTERN FORMATION,ONE CAN BUY AT PRICE 580 .
Chartbusters - chart - 183443934

Vote

Comment
Share
Add a comment
Its Berlin here-display-image
Reputation: 11,487  •  Sep 23 1:50 AM

ZYDUS LIFESCIENCES STOCK ANALYSIS.
In today's session stock gives a breakdown.
Cup & Handle pattern breakdown.
We will expect seing a some fall in more days.
That's my Analysis.
I do not give any advice about buying and selling.
The information provided is for educati......read more
Positional Bets - chart - 172420114

Vote

Comment
Share
Add a comment
Its Berlin here-display-image
Reputation: 11,487  •  Sep 23 1:48 AM

ZYDUS LIFESCIENCES STOCK ANALYSIS.
In today's session stock gives a breakdown.
Cup & Handle pattern breakdown.
We will expect seing a some fall in more days.
That's my Analysis.
I do not give any advice about buying and selling.
The information provided is for educati......read more
Chartbusters - chart - 172419911

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Sep 21 3:28 PM
Zydus Lifesciences gains on USFDA’s final approval for skin-care topical
Zydus Lifesciences gains on USFDA’s final approval for skin-care topical
“We have received final approval from the USFDA for Clindamycin Phosphate Gel USP. Clindamycin is an antibiotic which works by stopping the growth of bacteria and helps to decrease the number of acne lesions," Zydus Lifesciences said in a regulatory filing at the exchanges.
Moneycontrol

Vote

Comment
Share
Add a comment
Its Berlin here-display-image
Reputation: 11,487  •  Sep 19 1:37 AM

ZYDUS LIFESCIENCES STOCK ANALYSIS.
Stock create a Cup & Handle pattern.
We will wait for Breakout.
Time frame - weekly.
That's my Analysis.
I do not give any advice about buying and selling.
The information provided is for educational purposes only.
Please understand ......read more
Positional Bets - chart - 167641791

1 Vote

Comment
Share
Add a comment
Its Berlin here-display-image
Reputation: 11,487  •  Sep 19 1:36 AM

ZYDUS LIFESCIENCES STOCK ANALYSIS.
Stock create a Cup & Handle pattern.
We will wait for Breakout.
Time frame - weekly.
That's my Analysis.
I do not give any advice about buying and selling.
The information provided is for educational purposes only.
Please understand ......read more
Chartbusters - chart - 167641574

Vote

Comment
Share
Add a comment
D
Reputation: 13,822  •  Sep 19 12:14 AM

In weekly time frame chart analysis 📈📉
If stock will give breakout of this resistance zone then probably we will see upside momentum in this stock that's all are probability
Keep in your radar
For learning purpose
Do your own research analysis
Positional Bets - chart - 167633242

1 Vote

Comment
Share
Add a comment
Trading Addicttt-display-image
Reputation: 156,436  •  Sep 12 5:10 PM

ZYDUSLIFE FOR INTRADAY

TIME FRAME-15 MIN

Chartbusters - chart - 160494208

5 Votes

Comment
Share
Add a comment
MBA Investmentwala-display-image
Reputation: 10,768  •  Sep 5 12:46 AM

CMP: 620
Technical Indicator: Inside Candle
Chartbusters - chart - 152061004

Vote

Comment
Share
Add a comment
Rahul seth-display-image
Reputation: 2,007  •  Sep 5 12:31 AM

📈 INTRADAY STOCK 📈
BUY:- ZYUDUS LIFESCIENCES
ABOVE ⬆️ @625
TARGET 🎯:-630,635+++
STOPLOSS 📈:- As Per Your Risk Limit.
Chartbusters - chart - 152059909

Vote

Comment
Share
Add a comment
Rahul seth-display-image
Reputation: 2,007  •  Aug 25 12:37 AM

📈 INTRADAY STOCK 📈
BUY:- ZYUDUS LIFESCIENCES
ABOVE ⬆️ @642
TARGET 🎯:-645,648,652+++
STOPLOSS 📈:- As Per Your Risk Limit.
Chartbusters - chart - 142072097

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Aug 23 4:23 PM
Buy Zydus Lifesciences; target of Rs 750: Geojit
Buy Zydus Lifesciences; target of Rs 750: Geojit
Geojit is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 750 in its research report dated August 22, 2023.
Moneycontrol

Vote

Comment
Share
Add a comment
JaminChakkar-display-image
Reputation: 9,352  •  Aug 22 1:27 AM

High Return intraday Stock...
👇👇
Making a perfect triangle in 30 min time frame...
Chartbusters - chart - 137699859

Vote

Comment
Share
Add a comment
Arnab-display-image
Reputation: 528  •  Aug 20 3:17 PM

Script: Zydus Life
View: This stock has consolidated for a long time now and is looking for a perfect breakout/breakdown below these levels.

Timeframe: 1hr
Position: Positional
Entry: above 660 (Long). 635 (short)
Exit: 690+ (Long). 610(short)
Stoploss: 660 (long). 635(short)

*......read more
Positional Bets - chart - 136315725

2 Votes

Comment
Share
Add a comment
Suman Golui-display-image
Reputation: 3,024  •  Aug 19 7:05 PM

.Making A Nice SYMMETRICAL TRIANGLE
.Look for break out or Brakedown.
. SwingTrade
Chartbusters - chart - 136313910

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Aug 18 4:08 PM
Zydus Lifesciences gains on US FDA nod for anti-depressant drug
Zydus Lifesciences gains on US FDA nod for anti-depressant drug
The company is slated to be included in the Nifty Next 50 index on September 29 of the ongoing fiscal.
Moneycontrol

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Aug 17 2:38 AM
Accumulate Zydus Lifesciences; target of Rs 650: Prabhudas Lilladher
Accumulate Zydus Lifesciences; target of Rs 650: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Zydus Lifesciences with a target price of Rs 650 in its research report dated August 12, 2023.
Moneycontrol

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Aug 14 5:48 PM
Zydus Lifesciences down, Nuvama downgrades stock despite a strong Q1
Zydus Lifesciences down, Nuvama downgrades stock despite a strong Q1
Nuvama downgrades Zydus to ‘hold’. It says Q1 results are unlikely to be repeated, as exclusivity of epilepsy drug Trokendi is declining and revenue from blood cancer drug Revlimid remains 'lumpy'
Moneycontrol

Vote

Comment
Share
Add a comment
F
Reputation: 41,615  •  Aug 12 7:03 PM


Zyduslife in Montly Time Frame
Lets Wait For the Breakout...Lets see It Gives Breakout Or Takes Resistance from the level and Fall
Chartbusters - chart - 130692117

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Aug 11 6:23 PM
Zydus Lifesciences Q1 results: Net profit doubles to Rs 1,087 crore, beats estimates
Zydus Lifesciences Q1 results: Net profit doubles to Rs 1,087 crore, beats estimates
Revenue for the quarter came in at Rs 5,139.6crore, 29.6 percent higher than Rs 3,964.3 crore in the same quarter of the previous fiscal, the company said in an exchange filing.
Moneycontrol

Vote

Comment
Share
Add a comment
JaminChakkar-display-image
Reputation: 9,352  •  Aug 10 2:15 PM

1 Vote

Comment
Share
Add a comment
JaminChakkar-display-image
Reputation: 9,352  •  Aug 9 2:16 AM

Intraday Stock for tomorrow 09.08.23
Triangle pattern
Chartbusters - chart - 126508650

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Aug 3 4:43 PM
Zydus Lifesciences gains on USFDA nod to arthritis drug
Zydus Lifesciences gains on USFDA nod to arthritis drug
Zydus Lifesciences has received final approval from the USFDA to manufacture and market Indomethacin suppositories
Moneycontrol

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Jul 27 7:03 PM
Zydus Lifesciences gains 5% on USFDA nod for cancer drug
Zydus Lifesciences gains 5% on USFDA nod for cancer drug
The plerixafor injection, used by patients with certain types of cancer to prepare them for a stem cell transplant, will be manufactured at the group’s facility in Ahmedabad
Moneycontrol

1 Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Jul 12 6:03 PM
Zydus Lifescience Q1 PAT seen up 58.6% YoY to Rs 839.1 cr: Nirmal Bang
Zydus Lifescience Q1 PAT seen up 58.6% YoY to Rs 839.1 cr: Nirmal Bang
Net Sales are expected to increase by 24 percent Y-o-Y (up 0.8 percent Q-o-Q) to Rs 5,050.3 crore, according to Nirmal Bang.
Moneycontrol

Vote

Comment
Share
Add a comment
Ankit Kumar-display-image
Reputation: 1,432  •  Jul 12 2:23 PM

30 Min TF
Ascending Triangle Pattern
Good for upside.
Maitain SL at swing Low
Entry at breakout
Follow your rules
Chartbusters - chart - 99079248

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Jul 10 3:13 PM
Zydus Lifesciences gains on USFDA's all-clear for Ahmedabad unit
Zydus Lifesciences gains on USFDA's all-clear for Ahmedabad unit
The company has also received final approval from the United States Food and Drug Administration for Oxcarbazepine tablets. Oxcarbazepine is used to treat epilepsy
Moneycontrol

Vote

Comment
Share
Add a comment
JayTrader-display-image
Reputation: 74,102  •  Jul 3 5:01 AM

#ZYDUSLIFE is having a extremely narrow CPR. Keep a watch on the stock as it can give good pts on Mondays trading session
Chartbusters - chart - 90370629

1 Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Jun 30 11:38 PM
Buy Zydus Lifesciences; target of Rs 663: Sharekhan
Buy Zydus Lifesciences; target of Rs 663: Sharekhan
Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 663 in its research report dated June 28, 2023.
Moneycontrol

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Jun 30 3:23 PM
Zydus Lifesciences shares gain on tentative nod from USFDA for Palbociclib tablets
Zydus Lifesciences shares gain on tentative nod from USFDA for Palbociclib tablets
The product will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad.
Moneycontrol

Vote

Comment
Share
Add a comment
9amPrime-display-image
Reputation: 14,002  •  Jun 29 12:51 AM

#ZYDUSLIFE - Long Setup, Move is ON..

✅ Gave a breakout at 409.35 as per pattern shown in chart
✅ Now trading above Resistance of 570
✅ Next Resistance is at 670, 761
✅ Moved 42% in 38 weeks

Charts are self-explanatory. Levels of breakout, possible up-moves (where stock may fin......read more
Chartbusters - chart - 89161754

1 Vote

1 Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Jun 28 9:58 PM
What's on offer: What does buying stake in Mylab mean for Zydus?
What's on offer: What does buying stake in Mylab mean for Zydus?
Analysts predict the partial acquisition is a stepping stone for the company to venture into the diagnostic space at a later stage.
Moneycontrol

Vote

Comment
Share
Add a comment
NewsBot-display-image
Reputation: 181,721  •  Jun 24 7:28 PM
Zydus Life subsidiary to buy 6.5% stake in Mylab for Rs 106 crore
Zydus Life subsidiary to buy 6.5% stake in Mylab for Rs 106 crore
The proposed investment in Mylab will help the company to participate in growing diagnostics space which is expected to witness increased penetration through in-clinic solutions with Point of Care Testing devices, said Zydus Lifesciences.
Moneycontrol

Vote

Comment
Share
Add a comment
Load More Posts
Hero Img
Create your account on Frontpage
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.